Dextrose

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Dextrose
Generic name
DEXTROSE
Manufacturer
B. Braun Medical Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
8ccb10fe-75a5-440b-8cd4-b11f4e98f7b0
SPL ID
594041d9-3c28-4439-9ffa-8e8148ffcf8c
Version
26
Effective date
2026-10-21
Source export date
2026-11-13
Source partition
12
Source file
https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:55:24
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Neonatal Hypoglycemia : Closely monitor blood glucose concentrations to ensure adequate glycemic control. ( 5.1 ) Pulmonary Embolism and Respiratory Distress due to Pulmonary Vascular Precipitates : If signs of respiratory distress or pulmonary distress occur, stop the infusion and initiate a medical evaluation ( 5.2 ) Hyperglycemia or Hyperosmolar Hyperglycemic State : Monitor blood glucose and administer insulin as needed ( 5.3 ) Hypersensitivity Reactions : Monitor for signs and symptoms and discontinue infusion immediately if reactions occur ( 5.4 ) Phlebitis and Thrombosis : Remove catheter as soon as possible if thrombophlebitis develops. ( 2.2 , 5.5 ) Hyponatremia : Monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and neurologic status. ( 5.6 ) Infections, Refeeding complications, parenteral nutrition associated liver disease, hepatobiliary disorders : Monitor for signs and symptoms; laboratory parameters. ( 5.7 , 5.8 , 5.9 ) Aluminum Toxicity: Increased risk in patients with renal impairment, including preterm infants. ( 5.10 ) Electrolyte Imbalance and Fluid Overload : Monitor daily fluid balance, blood electrolyte levels, correct as needed. ( 5.11 ) 5.1 Neonatal Hypoglycemia Neonates, especially preterm neonates with low birth weight, are at increased risk of developing hypoglycemia. Closely monitor blood glucose concentration during treatment with Dextrose Injection (70%) to ensure adequate glycemic control in order to avoid potential long-term adverse effects. 5.2 Pulmonary Embolism and Respiratory Distress due to Pulmonary Vascular Precipitates Pulmonary vascular precipitates causing pulmonary vascular emboli (including some fatalities) and respiratory distress have been reported in patients receiving parenteral nutrition. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates; however, precipitates have also been reported even in the absence of phosphate salt in the solution. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. Visually inspect the prepared PN admixture containing Dextrose Injection (70%), the infusion set, and catheter for precipitates, prior to administration as well as periodically during the administration. If signs of respiratory distress or pulmonary embolism occur, stop the PN infusion and initiate a medical evaluation. 5.3 Hyperglycemia and Hyperosmolar Hyperglycemic State The use of Dextrose Injection (70%) in patients with impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death. Hyperglycemia is associated with an increase in serum osmolality, resulting in osmotic diuresis, dehydration, and electrolyte losses [see Warnings and Precautions (5.11) , Use in Specific Populations (8.4) ] . Patients with underlying CNS disease and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state. Monitor blood glucose levels and treat hyperglycemia to maintain levels within normal limits while administering the PN admixture containing Dextrose Injection (70%). Insulin may be administered or adjusted to maintain optimal blood glucose levels during Dextrose Injection (70%) administration. 5.4 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, have been reported with dextrose [see Adverse Reactions (6) ] . Stop administration of the PN admixture containing Dextrose Injection (70%) immediately if signs or symptoms of a hypersensitivity reaction develop. Initiate appropriate treatment as clinically indicated. 5.5 Phlebitis and Thrombosis Dextrose Injection (70%) is for admixture with amino acids or dilution with other compatible intravenous fluids. It is not for direct intravenous infusion. Administer solutions with an osmolarity of ≥ 900 mOsm/L through a central vein. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis [see Dosage and Administration (2.1) ] . If thrombophlebitis develops, remove the catheter as soon as possible. 5.6 Hyponatremia Dextrose Injection (70%) may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy and vomiting. The risk of hospital-acquired hyponatremia is increased in younger pediatric patients, geriatric patients, patients treated with diuretics, and patients with cardiac or pulmonary failure or with the syndrome of inappropriate antidiuretic hormone (SIADH) (e.g., postoperative patients, patients concomitantly treated with arginine vasopressin analogs or certain antiepileptic, psychotropic, and cytotoxic drugs) [see Drug Interactions (7.1) , Use in Specific Populations (8.4) ] . Rapid correction of hyponatremia is potentially dangerous with risk of serious neurologic complications such as osmotic demyelination syndrome (ODS) with risk of seizures and cerebral edema. To avoid complications, monitor serum sodium and chloride concentrations, fluid status, acid-based balance, and signs of neurologic complications. Avoid Dextrose Injection (70%) in patients with or at risk for hyponatremia. If use cannot be avoided, closely monitor serum sodium concentrations, chloride concentrations, fluid status, acid-base balance, and neurologic status [see Warnings and Precautions (5.11) ]. 5.7 Infections Patients who receive parenteral nutrition (PN), including admixtures containing Dextrose Injection (70%), are at high risk of infections because the nutritional components of PN can support microbial growth; patients on long-term parenteral nutrition may have additional risk factors for infection (e.g., immunosuppression related to malnutrition, other conditions, or concomitant drug use); and they receive the parenteral nutrition through intravenous catheters. To decrease the risk of infectious complications, ensure aseptic technique are used for catheter placement, catheter maintenance, and the preparation and administration of PN containing Dextrose Injection (70%). Monitor for signs and symptoms of infections, including fever and chills, as well as laboratory test results that might indicate infection (including leukocytosis and hyperglycemia) and perform frequent checks of the intravenous catheter insertion site for edema, redness, and discharge. 5.8 Refeeding Syndrome Administering PN, including admixtures containing Dextrose Injection (70%), to severely undernourished patients may result in refeeding syndrome, which is characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, closely monitor severely undernourished patients and slowly increase nutrient intake. 5.9 Parenteral Nutrition Associated Liver Disease and other Hepatobiliary Disorders Risk of Parenteral Nutrition Associated Liver Disease Parenteral nutrition-associated liver disease (PNALD), also referred to as intestinal failure-associated liver disease (IFALD), can present as cholestasis or hepatic steatosis, and may progress to steatohepatitis with fibrosis and cirrhosis (possibly leading to chronic hepatic failure). The etiology of PNALD is multifactorial; however, intravenously administered phytosterols (plant sterols) contained in plant-derived lipid formulations have been associated with development of PNALD. Other Hepatobiliary Disorders Hepatobiliary disorders including cholecystitis and cholelithiasis have developed in some parenteral nutrition-treated patients without preexisting liver disease. Monitor liver tests when administering PN admixtures containing Dextrose Injection (70%). Patients developing signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions. 5.10 Aluminum Toxicity Dextrose Injection (70%) contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Preterm neonates are particularly at risk because their kidneys are immature, and they require large amounts of concomitant calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including preterm neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system (CNS) and bone toxicity. Tissue loading may occur at even lower rates of administration. Exposure to aluminum from Dextrose Injection (70%) when administered at the maximum recommended dosage is not more than 0.5 mcg/kg/day [see Description (11) ] . When prescribing Dextrose Injection (70%) for use in PN solutions containing other small volume parenteral products, limit the total daily patient exposure to aluminum in the PN admixture to no more than 5 mcg/kg/day [see Use in Specific Populations (8.4) ] . 5.11 Electrolyte Imbalance and Fluid Overload Electrolyte deficits, particularly serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions. Depending on the volume and infusion rate, Dextrose Injection (70%) can cause fluid overload, including pulmonary edema. Avoid Dextrose Injection (70%) in patients at risk for fluid and/or solute overload. If use cannot be avoided in these patients, monitor fluid balance, electrolyte concentrations, and acid-base balance, especially during prolonged use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration and/or free water load.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Neonatal Hypoglycemia [see Warnings and Precautions (5.1) ] Pulmonary embolism and respiratory distress due to pulmonary vascular precipitates [see Warnings and Precautions (5.2) ] Hyperglycemia and hyperosmolar hyperglycemic state [see Warnings and Precautions (5.3) ] Hypersensitivity reactions [see Warnings and Precautions (5.4) ] Phlebitis and thrombosis [see Warnings and Precautions (5.5) ] Hyponatremia [see Warnings and Precautions (5.6) ] Infections [see Warnings and Precautions (5.7) ] Refeeding syndrome [see Warnings and Precautions (5.8) ] Parenteral nutrition associated liver disease and other hepatobiliary disorders [see Warnings and Precautions (5.9) ] Aluminum toxicity [see Warnings and Precautions (5.10) ] Electrolyte imbalance and fluid overload [see Warnings and Precautions (5.11) ] The following adverse reactions associated with the use of Dextrose Injection (70%) were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Administration site conditions : blister, erythema, extravasation, pain, phlebitis, vein damage, thrombosis Immune system disorders : anaphylaxis, angioedema, bronchospasm, chills, hypotension, pruritus, pyrexia, rash Cardiovascular disorders : cyanosis, volume overload The most common adverse reactions are hyperglycemia, hypersensitivity reactions, hyponatremia, infection both systemic and at the injection site, vein thrombosis or phlebitis, and electrolyte imbalance. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact B. Braun Medical Inc. at 1-833-425-1464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.